Ashland Inc. (ASH)

Revenue by Geography

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	2013 - 2020
Period Ending	Jun 30, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021	2013 - 2020
United States Revenue	-	624.00M	Log In	Log In	Log In	Upgrade
International Revenue	-	1.49B	Log In	Log In	Log In	Upgrade
Revenue (Other)	1.87B	-	Log In	Log In	Log In	Upgrade
Revenue (Total)	1.87B	2.11B	Log In	Log In	Log In	Upgrade

Revenue

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	2013 - 2020
Period Ending	Jun 30, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021	2013 - 2020
Life Sciences Revenue	660.00M	810.00M	Log In	Log In	Log In	Upgrade
Personal Care Revenue	589.00M	634.00M	Log In	Log In	Log In	Upgrade
Specialty Additives Revenue	524.00M	572.00M	Log In	Log In	Log In	Upgrade
Intermediates Revenue	139.00M	144.00M	Log In	Log In	Log In	Upgrade
Eliminations from Revenue	-43.00M	-47.00M	Log In	Log In	Log In	Upgrade
Revenue (Total)	1.87B	2.11B	Log In	Log In	Log In	Upgrade

EBIT

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	2013 - 2020
Period Ending	Jun 30, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021	2013 - 2020
Life Sciences Operating Income	-258.00M	168.00M	Log In	Log In	Log In	Upgrade
Personal Care Operating Income	78.00M	73.00M	Log In	Log In	Log In	Upgrade
Specialty Additives Operating Income	-334.00M	-32.00M	Log In	Log In	Log In	Upgrade
Intermediates Operating Income	13.00M	29.00M	Log In	Log In	Log In	Upgrade
Unallocated and Other Operating Income	-303.00M	-264.00M	Log In	Log In	Log In	Upgrade
Operating Income (Other)	501.00M	-6.00M	Log In	Log In	Log In	Upgrade
Operating Income (Total)	-303.00M	-32.00M	Log In	Log In	Log In	Upgrade

EBITDA

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	2013 - 2020
Period Ending	Jun 30, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021	2013 - 2020
Life Sciences EBITDA	195.00M	229.00M	Log In	Log In	Log In	Upgrade
Personal Care EBITDA	148.00M	152.00M	Log In	Log In	Log In	Upgrade
Specialty Additives EBITDA	87.00M	89.00M	Log In	Log In	Log In	Upgrade
Intermediates EBITDA	26.00M	42.00M	Log In	Log In	Log In	Upgrade
Unallocated and Other EBITDA	-303.00M	-264.00M	Log In	Log In	Log In	Upgrade
Operating Income (Other)	-456.00M	-280.00M	Log In	Log In	Log In	Upgrade
Operating Income (Total)	-303.00M	-32.00M	Log In	Log In	Log In	Upgrade

Key Performance Indicators

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	2013 - 2020
Period Ending	Jun 30, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021	2013 - 2020
Change in Sales Due to Volume	-68.00M	1.00M	Log In	Log In	Log In	Upgrade
Change in Sales Due to Product Pricing/Mix	-51.00M	-78.00M	Log In	Log In	Log In	Upgrade

Updated Jul 29, 2025. Data Source: Fiscal.ai.